Flumazenil-precipitated withdrawal in healthy volunteers following repeated diazepam exposure

Miriam Z. Mintzer, Roland R Griffiths

Research output: Contribution to journalArticle

Abstract

Rationale: Parametric preclinical studies of the benzodiazepine antagonist flumazenil have contributed to the understanding of the physical dependence associated with chronic benzodiazepine use. However, few parametric studies have been conducted in human participants. Objective: This study was designed to assess the effect of duration of benzodiazepine exposure on the intensity of flumazenil-precipitated withdrawal in healthy volunteers. Method: Participants were randomly assigned to receive either oral diazepam (15 mg/70 kg; n=10) or placebo (n=8) capsules nightly for 28 days. Effects of flumazenil (1 mg/70 kg, intravenously administered) were assessed in challenge sessions conducted before capsule ingestion, and after 1, 7, 14, and 28 days of capsule ingestion. Results: Flumazenil produced a profile of participant-rated effects consistent with benzodiazepine withdrawal that peaked immediately after completion of the 5-min flumazenil injection and rapidly dissipated thereafter. The magnitude of these effects was comparable after 7, 14, and 28 days of diazepam. Flumazenil also produced modest elevations in blood pressure and decreases in skin temperature in the diazepam group, both of which were sustained throughout the approximate 60-min session. Conclusions: These findings support previous human research studies indicating that flumazenil precipitates withdrawal after short chronic exposure to benzodiazepines and suggests that duration of exposure does not influence the intensity of withdrawal beyond the first week of exposure.

Original languageEnglish (US)
Pages (from-to)259-267
Number of pages9
JournalPsychopharmacology
Volume178
Issue number2-3
DOIs
StatePublished - Mar 2005

Fingerprint

Flumazenil
Diazepam
Healthy Volunteers
Benzodiazepines
Capsules
Eating
Skin Temperature
Placebos
Blood Pressure
Injections
Research

ASJC Scopus subject areas

  • Pharmacology

Cite this

Flumazenil-precipitated withdrawal in healthy volunteers following repeated diazepam exposure. / Mintzer, Miriam Z.; Griffiths, Roland R.

In: Psychopharmacology, Vol. 178, No. 2-3, 03.2005, p. 259-267.

Research output: Contribution to journalArticle

@article{307925c448814b39ad178360e50448a6,
title = "Flumazenil-precipitated withdrawal in healthy volunteers following repeated diazepam exposure",
abstract = "Rationale: Parametric preclinical studies of the benzodiazepine antagonist flumazenil have contributed to the understanding of the physical dependence associated with chronic benzodiazepine use. However, few parametric studies have been conducted in human participants. Objective: This study was designed to assess the effect of duration of benzodiazepine exposure on the intensity of flumazenil-precipitated withdrawal in healthy volunteers. Method: Participants were randomly assigned to receive either oral diazepam (15 mg/70 kg; n=10) or placebo (n=8) capsules nightly for 28 days. Effects of flumazenil (1 mg/70 kg, intravenously administered) were assessed in challenge sessions conducted before capsule ingestion, and after 1, 7, 14, and 28 days of capsule ingestion. Results: Flumazenil produced a profile of participant-rated effects consistent with benzodiazepine withdrawal that peaked immediately after completion of the 5-min flumazenil injection and rapidly dissipated thereafter. The magnitude of these effects was comparable after 7, 14, and 28 days of diazepam. Flumazenil also produced modest elevations in blood pressure and decreases in skin temperature in the diazepam group, both of which were sustained throughout the approximate 60-min session. Conclusions: These findings support previous human research studies indicating that flumazenil precipitates withdrawal after short chronic exposure to benzodiazepines and suggests that duration of exposure does not influence the intensity of withdrawal beyond the first week of exposure.",
author = "Mintzer, {Miriam Z.} and Griffiths, {Roland R}",
year = "2005",
month = "3",
doi = "10.1007/s00213-004-2009-1",
language = "English (US)",
volume = "178",
pages = "259--267",
journal = "Psychopharmacology",
issn = "0033-3158",
publisher = "Springer Verlag",
number = "2-3",

}

TY - JOUR

T1 - Flumazenil-precipitated withdrawal in healthy volunteers following repeated diazepam exposure

AU - Mintzer, Miriam Z.

AU - Griffiths, Roland R

PY - 2005/3

Y1 - 2005/3

N2 - Rationale: Parametric preclinical studies of the benzodiazepine antagonist flumazenil have contributed to the understanding of the physical dependence associated with chronic benzodiazepine use. However, few parametric studies have been conducted in human participants. Objective: This study was designed to assess the effect of duration of benzodiazepine exposure on the intensity of flumazenil-precipitated withdrawal in healthy volunteers. Method: Participants were randomly assigned to receive either oral diazepam (15 mg/70 kg; n=10) or placebo (n=8) capsules nightly for 28 days. Effects of flumazenil (1 mg/70 kg, intravenously administered) were assessed in challenge sessions conducted before capsule ingestion, and after 1, 7, 14, and 28 days of capsule ingestion. Results: Flumazenil produced a profile of participant-rated effects consistent with benzodiazepine withdrawal that peaked immediately after completion of the 5-min flumazenil injection and rapidly dissipated thereafter. The magnitude of these effects was comparable after 7, 14, and 28 days of diazepam. Flumazenil also produced modest elevations in blood pressure and decreases in skin temperature in the diazepam group, both of which were sustained throughout the approximate 60-min session. Conclusions: These findings support previous human research studies indicating that flumazenil precipitates withdrawal after short chronic exposure to benzodiazepines and suggests that duration of exposure does not influence the intensity of withdrawal beyond the first week of exposure.

AB - Rationale: Parametric preclinical studies of the benzodiazepine antagonist flumazenil have contributed to the understanding of the physical dependence associated with chronic benzodiazepine use. However, few parametric studies have been conducted in human participants. Objective: This study was designed to assess the effect of duration of benzodiazepine exposure on the intensity of flumazenil-precipitated withdrawal in healthy volunteers. Method: Participants were randomly assigned to receive either oral diazepam (15 mg/70 kg; n=10) or placebo (n=8) capsules nightly for 28 days. Effects of flumazenil (1 mg/70 kg, intravenously administered) were assessed in challenge sessions conducted before capsule ingestion, and after 1, 7, 14, and 28 days of capsule ingestion. Results: Flumazenil produced a profile of participant-rated effects consistent with benzodiazepine withdrawal that peaked immediately after completion of the 5-min flumazenil injection and rapidly dissipated thereafter. The magnitude of these effects was comparable after 7, 14, and 28 days of diazepam. Flumazenil also produced modest elevations in blood pressure and decreases in skin temperature in the diazepam group, both of which were sustained throughout the approximate 60-min session. Conclusions: These findings support previous human research studies indicating that flumazenil precipitates withdrawal after short chronic exposure to benzodiazepines and suggests that duration of exposure does not influence the intensity of withdrawal beyond the first week of exposure.

UR - http://www.scopus.com/inward/record.url?scp=15044351604&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=15044351604&partnerID=8YFLogxK

U2 - 10.1007/s00213-004-2009-1

DO - 10.1007/s00213-004-2009-1

M3 - Article

C2 - 15452683

AN - SCOPUS:15044351604

VL - 178

SP - 259

EP - 267

JO - Psychopharmacology

JF - Psychopharmacology

SN - 0033-3158

IS - 2-3

ER -